Nona Biosciences, a global biotechnology company specializing in providing comprehensive solutions from "Idea to IND" (I to ITM), announced that BeiGene, Ltd. has exercised its exclusive option to acquire worldwide rights for the development, manufacturing, and commercialization of an innovative antibody-drug conjugate (ADC) developed by DualityBio, a key collaborator of Nona Biosciences.

The ADC, designed for targeted cancer therapy, was created through a collaboration agreement established between Nona Biosciences and DualityBio in 2022. According to the agreement, Nona Biosciences granted DualityBio exclusive rights to a portfolio of proprietary monoclonal antibodies specifically targeting certain tumor markers. These monoclonal antibodies serve as the foundational components for developing groundbreaking ADC candidates. By linking potent cytotoxic agents to tumor-specific antibodies, the ADCs deliver enhanced precision and efficacy in destroying cancer cells while minimizing off-target toxicity.

This strategic partnership has aimed to accelerate the development of first-in-class ADCs addressing unmet clinical needs, leveraging Nona Biosciences' advanced antibody discovery platforms and DualityBio's expertise in ADC technology. The recent decision by BeiGene to acquire global rights marks a significant milestone, highlighting the potential of this collaborative innovation to advance next-generation oncology therapeutics for patients worldwide.